PMID- 33856733
OWN - NLM
STAT- MEDLINE
DCOM- 20210927
LR  - 20210927
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 35
IP  - 7
DP  - 2021 Jul
TI  - Inflammatory markers response to crocin supplementation in patients with type 2 
      diabetes mellitus: A randomized controlled trial.
PG  - 4022-4031
LID - 10.1002/ptr.7124 [doi]
AB  - Inflammation and oxidative stress is a risk factor for the development of 
      long-term consequences in patients with type 2 diabetes mellitus (T2DM). This 
      study was designed to investigate the effects of crocin consumption on oxidative 
      stress and inflammatory markers in patients with T2DM. In this clinical trial 
      with a parallel-group design, 50 patients with T2DM were randomly assigned to 
      either the crocin or the placebo group. The crocin group received 15 mg crocin 
      twice daily, whereas the placebo group received corresponding placebos. At 
      baseline and the end of week 12, serum high sensitive C-reactive protein 
      (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), nuclear 
      factor-kappaB (NF-kappaB), and malondialdehyde (MDA) were measured. Compared with placebo 
      group, crocin reduced hs-CRP (-1.03 vs. 1.42, p = .007), TNF-a (-0.8 vs. 0.28, 
      p = .009), and NF-kappaB (-0.39 vs. 0.01, p = .047) after 12 weeks intervention; 
      these improvements were also significant in comparison with the baseline values. 
      Plasma IL-6 decreased significantly in the crocin group at the end of week 12 
      compared to baseline (p = .037), whereas no significant change was observed in 
      the placebo group. Plasma concentration of MDA did not change within and between 
      groups after intervention. This study indicates that daily administration of 
      30 mg crocin supplement to patients with T2DM reduces the concentrations of 
      hs-CRP, TNF-a, and NF-kappaB which are involved in the pathogenesis of complications 
      of T2DM.
CI  - (c) 2021 John Wiley & Sons Ltd.
FAU - Behrouz, Vahideh
AU  - Behrouz V
AD  - Department of Nutrition, Faculty of Public Health, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Sohrab, Golbon
AU  - Sohrab G
AUID- ORCID: 0000-0002-3348-2734
AD  - Department of Clinical Nutrition and Dietetics, Faculty of Nutrition and Food 
      Technology, National Nutrition and Food Technology Research Institute, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Hedayati, Mehdi
AU  - Hedayati M
AD  - Cellular and Molecular Endocrine Research Center, Research Institute for 
      Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Sedaghat, Meghdad
AU  - Sedaghat M
AD  - Department of Internal Medicine, Imam-Hossein General Hospital, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
LA  - eng
GR  - 97003952/Iran National Science Foundation/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20210415
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Biomarkers)
RN  - 36-88-4 (Carotenoids)
RN  - 877GWI46C2 (crocin)
SB  - IM
MH  - Biomarkers/blood
MH  - Carotenoids/*therapeutic use
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dietary Supplements
MH  - Humans
MH  - Inflammation/blood
MH  - Oxidative Stress
OTO - NOTNLM
OT  - crocin
OT  - diabetes
OT  - inflammation
OT  - oxidative stress
OT  - saffron
EDAT- 2021/04/16 06:00
MHDA- 2021/09/28 06:00
CRDT- 2021/04/15 12:28
PHST- 2021/03/08 00:00 [revised]
PHST- 2020/12/05 00:00 [received]
PHST- 2021/03/26 00:00 [accepted]
PHST- 2021/04/16 06:00 [pubmed]
PHST- 2021/09/28 06:00 [medline]
PHST- 2021/04/15 12:28 [entrez]
AID - 10.1002/ptr.7124 [doi]
PST - ppublish
SO  - Phytother Res. 2021 Jul;35(7):4022-4031. doi: 10.1002/ptr.7124. Epub 2021 Apr 15.